Cicero, Arrigo F. G. http://orcid.org/0000-0002-4367-3884
Fogacci, Federica
Stoian, Anca Pantea
Vrablik, Michal
Al Rasadi, Khalid
Banach, Maciej
Toth, Peter P.
Rizzo, Manfredi
Funding for this research was provided by:
Alma Mater Studiorum - Università di Bologna
Article History
Accepted: 6 July 2021
First Online: 4 August 2021
Declarations
:
: This article does not contain original data from studies with human or animal subjects.
: The authors declare that the current research was conducted independently, in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. <i>Arrigo F.G. Cicero</i> has received grants from Meda-Mylan SpA, Menarini IFR SpA and Sharper SpA. <i>Federica Fogacci</i> received grants from Meda-Mylan SpA and Neogen SpA. <i>Anca Pantea Stoian</i> is currently Vice President of Romanian National Diabetes Committee, and she has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by many companies including AstraZeneca, Boehringer Ingelheim, Medtronic, Eli Lilly, Merck, Novo Nordisk, Novartis, Roche Diagnostics, and Sanofi. <i>Maciej Banach</i> is in the speakers bureau for Amgen, Daichii Sankyo, Esperion, Herbapol, KRKA, MSD, Mylan, Novartis, Novo Nordisk, Sanofi-Aventis, Servier; consultant to Abbott Vascular, Akcea, Amgen, Daichii Sankyo, Esperion, Lilly, MSD, Resverlogix, Sanofi-Aventis; received grants from Amgen, Mylan, Sanofi, and Valeant. <i>Peter P. Toth</i> is a member of the speakers bureau for Amarin, Amgen, Esperion, and Novo Nordisk; he is a consultant to Amarin, Amgen, Kowa, Merck, Resverlogix, and Theravance. <i>Manfredi Rizzo</i> is full-time Professor of Internal Medicine at University of Palermo, Italy, and currently Medical Director, Novo Nordisk Eastern Europe; he has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp and Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi, and Servier. None of the above companies had any role in this article, which was written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.